Jul. 14 at 7:09 PM
Jefferies🏁
$JBIO Buy-
$16
$VRTX $OTSKF
Jefferies said in its initiation report:
"We like
$JBIO's long-acting anti-APRIL (JADE101) in IgAN:
1) our PK work suggests '101 can achieve Q8/12W dosing,
2) we think efficacy will be as good as povetacicept w/ pot'l upside on % clinical remission,
3) we expect tolerable safety profile w/o increased serious infections,
4) we see oppty for disease modifying tx w/ longer dosing interval in IgAN.
We model
$915M risk-adj. PS for '101 (POS 30%). Co also has
$255M cash/cash eq. w/ runway to '27."
